Bruno Pougault: Oral Anticoagulants Are Essential, But Not a ‘Fix-All’
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn about a recent article by Eva Soler-Espejo et al, published in JAHA:
”Oral anticoagulants: Essential, but not a ‘fix-all’.
A huge thank you to the authors of this recent study in JAHA (DOI: 10.1161/JAHA.125.046694) for highlighting the reality of residual risk.
Even with optimal treatment, the risk of stroke in AFib patients persists.
This research is a vital reminder that we must look beyond the prescription: managing comorbidities and lifestyle remains just as crucial as the medication itself.
Great work by the team for pushing the boundaries of comprehensive cardiovascular care!”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler-Espejo, Yang Chen, José M. Rivera-Caravaca, María P. Ramos-Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on JAHA
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!